To see only press releases which have been disclosed pursuant to legislation or other regulations, please select “Regulatory releases” below.
Completion of capital increase in Initiator Pharma
Initiator Pharma A/S (“Initiator” or the “Company”) has today completed the capital increase directed at members of executive management and key management under the long term incentive program for 2023 (“LTI2023-program”), which was announced on 14 October 2024.
Finalization of share buyback program in Initiator Pharma
Initiator Pharma A/S (“Initiator” or the “Company”) has today finalized the share buyback that was announced on 14 October 2024.
Decision to issue new shares and conduct share buyback, as well as the sale of shares in connection with the long-term incentive program for 2023
The Board of Directors of Initiator Pharma A/S, company reg. (CVR) no. 37663808, (“Initiator” or the “Company”) has today resolved to carry out a capital increase directed at members of executive management and key management under the long term incentive program for 2023 (“LTI2023-program”) and to conduct a buyback of shares through the market in order to sell such treasury shares to the board of directors under the LTI2023-program.
Initiator Pharma’s international patent application regarding pudafensine’s dosage regime for the treatment of erectile dysfunction has been published
Initiator Pharma A/S, a clinical-stage biotech company, today announced that its international (PCT) patent application no. PCT/EP2024/050061 directed to a dosage regime of pudafensine for treatment of erectile dysfunction was published on July 11, 2024, under publication number WO2024/146892. The publicly available pudafensine patent portfolio now comprises a composition of matter patent and three medical use patent families within the fields of erectile dysfunction, female sexual dysfunction, and pain. Together, they confer a multi layered patent protection for pudafensine until 2044, with possibilities for patent term extension up to an additional five years.
Initiator Pharma A/S – Resolutions of the annual general meeting 2024
The annual general meeting of Initiator Pharma A/S (reg. no. 37663808 the “Company”) was held at the office of DLA Piper Denmark, Oslo Plads 2, 2100 Copenhagen OE on 24 May 2024 at 10.00 AM CEST.
Annual report and Remuneration report 2023 for Initiator Pharma A/S
Initiator Pharma’s Annual Report 2023 and Remuneration Report 2023 has now been published and is available on the company´s home page.